Recro to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020
August 06, 2020 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for development,...
Recro Highlights Manufacturing Readiness For Essential Drugs and Medical Supplies
June 11, 2020 10:00 ET
|
Recro Pharma, Inc.
Company Owns and Operates Over 120,000 Square Feet of U.S. cGMP and DEA-Licensed Contract Development and Manufacturing Facilities Focused on Creating Oral, Solid Dose Drug Products Long, Proven...
Recro Reports First Quarter 2020 Financial Results and Provides Update on COVID-19 Response and Impact
May 11, 2020 07:00 ET
|
Recro Pharma, Inc.
Company Generates $21.8 Million in First Quarter 2020 Revenues Revises Annual Revenue Guidance for 2020 MALVERN, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a leading...
Recro to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 11, 2020
May 08, 2020 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., May 08, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development,...
Recro Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters
May 01, 2020 16:05 ET
|
Recro Pharma, Inc.
MALVERN, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) (the “Company”), a high-performing, revenue generating contract development and manufacturing organization, today...
Recro Reports Financial Results for the Year Ended 2019
March 04, 2020 07:00 ET
|
Recro Pharma, Inc.
Recro Completes Separation of Baudax Bio and Is Now a Pure Play CDMO Business Company Sets Annual Revenue Record; 2019 Revenues of $99.2 Million Company to Host Conference Call Today at 8:00 AM ET ...
Recro to Report Year End 2019 Financial Results and Host Conference Call and Webcast on March 4, 2020
March 02, 2020 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., March 02, 2020 (GLOBE NEWSWIRE) -- Recro, Inc. (NASDAQ:REPH) a leading contract development and manufacturing organization (CDMO) with integrated solutions for the development,...
Recro Completes Separation of Baudax Bio and Becomes a Dedicated Contract Development and Manufacturing Organization
November 21, 2019 16:30 ET
|
Recro Pharma, Inc.
Recro Capitalizing on Strong and Growing CDMO Business Business Poised to Continue Driving Revenue and Begin Generating Profits Recro Will Continue to Trade on NASDAQ Under Ticker Symbol “REPH” ...
Baudax Bio™ Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies
November 21, 2019 07:00 ET
|
Recro Pharma, Inc.; Baudax Bio, Inc.
Company Launches with $19 Million in Funding and Rights to IV Meloxicam, Along with Other Clinical-Stage Pipeline Assets Trading of “BXRX” Begins Tomorrow on NASDAQ MALVERN, Pa., Nov. 21, 2019 ...
Recro Pharma Announces Effectiveness of Baudax Bio Form 10 Registration Statement
November 13, 2019 07:00 ET
|
Recro Pharma, Inc.
Separation of Baudax Bio as Independent Company Expected to be Completed With Distribution on November 21, 2019 Baudax Bio Common Stock Approved for Listing on the NASDAQ Capital Market MALVERN,...